OBJECTIVES This study sought to present the U.K. experience to date with the second-generation LOTUS bioprosthesis (Boston Scientific, Natick, Massachusetts).
Second-generation devices aim to improve on firstgeneration devices in some of these regards. The LOTUS bioprosthesis is a second-generation device that combines repositionability with an adaptive seal to reduce aortic regurgitation. We present our experience of implantation of the LOTUS device to this date in the United Kingdom. The procedure itself was carried out as previously described (6) . Briefly, after transarterial access was gained via the preferred access route, a Safari wire (Boston Scientific, Natick, Massachusetts) with a pre- Values are mean AE SD or n (%).
METHODS

All centers in the United
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RESULTS
BASELINE CHARACTERISTICS. Table 1 Values are n (%).
FIGURE 1 Changes in Peak Aortic Valve Gradient and Aortic Valve Area
Changes in peak aortic valve gradient and aortic valve area in patients with aortic stenosis and/or mixed aortic valve disease before and after implantation of a Lotus device. Table 4 . The percutaneous treatment of vessel perforation and dissection via either the contralateral femoral route or radial approach was used successfully in 5 cases. Two of the cases were due to issues in deploying the closure device, whereas the remaining 3 cases were due to ongoing bleeding despite appropriate deployment of the closure device.
The definition of acute kidney injury included stages 1 to 3. Of the 18 patients (7.9%) who developed an acute kidney injury, only 1 patient (0.4%) required renal replacement therapy.
The incidence of stroke during the inpatient admission was 3.9% (n ¼ 9).
The baseline pacemaker rate pre-procedure was 11.8% (n ¼ 27). The pacemaker implantation rate was 31.8% with a median time to insertion of 3.0 AE 3. 
DISCUSSION
This is the largest published analysis of the use of the LOTUS bioprosthesis in an all-comers cohort. Inhospital mortality is lower than previous comparable reported series (7) (8) (9) , and the rate of significant aortic regurgitation is strikingly low.
Our patient cohort had a lower mean Logistic
EuroScore when compared to older registries (7-9).
The inpatient mortality rate of 1.8% includes the learning curve in each center and therefore is suggestive of an excellent safety profile.
Transfemoral access is associated with vascular complications with reported rates of up to 20%.
The strong association with increased morbidity and mortality is well documented (10) . Although the firstgeneration devices required a large introducer sheath bailout valve-in-valve reducing manipulation of the aortic root and arch. Nonetheless, in our series, the stroke rate was significant at 3.9%. Our observation is limited by the fact that we did not have any information regarding the severity of cerebrovascular accident. Therefore, we cannot infer the effect of stroke on long term disability and morbidity in our cohort.
The 
CONCLUSIONS
There has been a rapid expansion of commercially available transcatheter aortic bioprostheses on the market over the last 3 years with the primary aim of improving deliverability and reducing complication rates. Our analysis reflects the first real-world experience with the second-generation LOTUS bioprosthesis.
Our results are comparable to the REPRISE 2 trial data.
In particular, TAVR with the LOTUS device is associated with a low incidence of aortic regurgitation compared with first-generation devices. The need for a permanent pacemaker following the procedure is still significant and is similar to first-generation selfexpanding prosthesis. In-hospital mortality was rare and supports the safety of this device. WHAT IS NEW? Our study shows that the second-generation LOTUS device has a good safety profile and in particular is associated with a very low incidence of aortic regurgitation.
WHAT IS NEXT? The long-term safety and performance of this device needs to be confirmed. Rampat et al.
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